 |
ADM BIOPOLIS |
Microbiome Analysis |
Diagnostic |
Autoimmune & Inflammation
Dermatology
Digestive System
Metabolic / Endocrinology
Women´s health |
Various |
5RTM |
Worldwide |
Microbiome Analysis
Therapeutic area:
Autoimmune & Inflammation
Dermatology
Digestive System
Metabolic / Endocrinology
Women´s health
|
 |
ADmit Therapeutics |
ADmit Test |
Biomarkers / Diagnostic |
Central Nervous System |
Alzheimer's disease in prodromic stage (Mild Cognitive Impairment) |
3CV |
Spain, Australia |
ADmit Test
Therapeutic area:
Central Nervous System
|
 |
ADNTRO |
ADNTRO Pharmacogenetics |
Biomarkers |
Others |
Clinical dosing guidelines for more than 60 drugs - haplotypes analysis |
5RTM |
Worldwide |
ADNTRO Pharmacogenetics
Therapeutic area:
Others
|
|
ADNTRO |
Biomarkers identification |
Biomarkers |
Central Nervous System |
GWAS to identify genetic variants associated with Alzheimer. |
1R+D |
Spain |
Biomarkers identification
Therapeutic area:
Central Nervous System
|
|
ADNTRO |
ADNTRO Clinical Algorithm |
Others |
Others |
Algorithm to detect pathogenic variants for patients that had been already diagnosed (currently working with oncology patients) |
5RTM |
Worldwide |
ADNTRO Clinical Algorithm
Therapeutic area:
Others
|
|
ADNTRO |
ADNTRO kit |
Others |
Others |
Polygenic risk scores (PRSs) for complex diseases. A useful tool to support medical diagnosis and for diseases prevention. |
5RTM |
Worldwide |
ADNTRO kit
Therapeutic area:
Others
|
 |
Agrenvec |
Recombinant proteins, COVID-19 antigens |
Biomarkers / Diagnostic |
Infections |
COVID-19 antigens for immunoassay |
3CV |
SPAIN |
Recombinant proteins, COVID-19 antigens
Therapeutic area:
Infections
|
 |
Altum Sequencing |
Clonesight |
Biomarkers / Diagnostic |
Cancer |
Lung |
2PreV |
Europe |
Clonesight
Therapeutic area:
Cancer
|
|
Altum Sequencing |
Clonesight |
Biomarkers / Diagnostic |
Cancer |
Follicular Lymphoma |
3CV |
Europe |
Clonesight
Therapeutic area:
Cancer
|
|
Altum Sequencing |
Clonesight |
Biomarkers / Diagnostic |
Cancer |
Acute Myeloid Leukemia(AML) |
3CV |
Europe |
Clonesight
Therapeutic area:
Cancer
|
 |
AMADIX (Advanced marker discovery) |
PancreaDix |
Biomarkers / Diagnostic |
Cancer |
Innovative non-invasive blood-based test for early detection of pancreatic cancer and preneoplastic lesions |
3CV |
Spain |
PancreaDix
Therapeutic area:
Cancer
|
|
AMADIX (Advanced marker discovery) |
DiagnoLung |
Biomarkers / Diagnostic |
Cancer |
Innovative non-invasive blood-based test for early detection of lung cancer in high-risk screening population and in patients with indeterminate pulmonary nodules |
3CV |
Spain |
DiagnoLung
Therapeutic area:
Cancer
|
 |
APTUS Biotech |
PrediApt |
Biomarkers / Diagnostic |
Cancer |
Aptusbiotech is developing two prognostic applications in response to platinum derivative treatment in lung cancer using MAFG as diagnostic biomarker and based on aptamers |
2PreV |
Spain |
PrediApt
Therapeutic area:
Cancer
|
|
APTUS Biotech |
Apta-Leish |
Diagnostic |
Infections |
Leishmaniasis diagnosis based on aptamers |
1R+D |
Spain |
Apta-Leish
Therapeutic area:
Infections
|
|
APTUS Biotech |
PHITBAC |
Diagnostic |
Infections |
Aptus is developing nanophotonic biosensors for the diagnosis and clinical management of bacterial infections at the point-of-care. We are selecting novel and exclusive aptamers for the detection of specific antibiotics used in clinics |
1R+D |
|
PHITBAC
Therapeutic area:
Infections
|
|
APTUS Biotech |
AptaDetect-HCV |
Diagnostic |
Infections |
Hepatitis C virus (HCV) diagnosis based on aptamers |
1R+D |
Spain |
AptaDetect-HCV
Therapeutic area:
Infections
|
 |
Araclon Biotech |
ABtest-IA |
Biomarkers |
Central Nervous System |
Alzheimer�s disease diagnostic service in the early stages. ISO9001 certified. |
5RTM |
Worldwide |
ABtest-IA
Therapeutic area:
Central Nervous System
|
|
Araclon Biotech |
ABtest-MS |
Biomarkers |
Central Nervous System |
Alzheimer�s disease diagnostic service in the early stages by mass spectrometry. ISO9001 certified. |
5RTM |
Worldwide |
ABtest-MS
Therapeutic area:
Central Nervous System
|
 |
ATRYS HEALTH |
Home-Care HTA |
Patient monitoring equipment |
Others |
mediciÃn, valoraciÃn y seguimiento de pacientes con HTA |
5RTM |
|
Home-Care HTA
Therapeutic area:
Others
|
|
ATRYS HEALTH |
radioproliq |
Biomarkers |
Cancer |
Firma molecular en biopsia léquida para respuesta a radioterapia y recaéda temprana en cáncer de prÃstata |
2PreV |
|
radioproliq
Therapeutic area:
Cancer
|
|
ATRYS HEALTH |
Personalized Medicine |
Patient monitoring equipment |
Cancer |
Expert system for breast and colon cancer patient management |
3CV |
Spain |
Personalized Medicine
Therapeutic area:
Cancer
|
|
ATRYS HEALTH |
home care Diabetes |
Patient monitoring equipment |
Metabolic / Endocrinology |
diabetes |
5RTM |
|
home care Diabetes
Therapeutic area:
Metabolic / Endocrinology
|
|
ATRYS HEALTH |
Personalized Medicine |
Biomarkers |
Cancer |
Patient stratification in glioma |
3CV |
Spain |
Personalized Medicine
Therapeutic area:
Cancer
|
|
ATRYS HEALTH |
oncliq |
Biomarkers / Diagnostic |
Cancer |
Desarrollo de una plataforma dinámica de detecciÃn rápida de alteraciones moleculares accionables a partir de biopsias léquidas y sÃlidas de pacientes oncolÃgicos |
1R+D |
|
oncliq
Therapeutic area:
Cancer
|
|
ATRYS HEALTH |
Personalized Medicine |
Biomarkers / Diagnostic |
Cancer |
Patient stratification for difuse large b-cell lymphoma therapy |
3CV |
Spain |
Personalized Medicine
Therapeutic area:
Cancer
|
|
ATRYS HEALTH |
mAb for diagnosis and prognosis of brain tumors and lesions |
Biomarkers / Diagnostic |
Cancer
Central Nervous System |
Glioblastoma, neurodegenerative disease |
1R+D |
Spain |
mAb for diagnosis and prognosis of brain tumors and lesions
Therapeutic area:
Cancer
Central Nervous System
|
|
ATRYS HEALTH |
inmunoterapia |
Biomarkers |
Cancer |
CaracterizaciÃn inmunolÃgica y molecular en biopsia léquida de pacientes de cáncer de pulmÃn para inmunoterapia |
1R+D |
|
inmunoterapia
Therapeutic area:
Cancer
|
|
ATRYS HEALTH |
telecardio |
Diagnostic/Imaging |
Cardiovascular and circulatory systems |
Herramientas de Telemedicina para la DetecciÃn y PrevenciÃn de Enfermedades Cardiovasculares |
2PreV |
|
telecardio
Therapeutic area:
Cardiovascular and circulatory systems
|
|
ATRYS HEALTH |
surveprost |
Biomarkers |
Cancer |
Desarrollo de firma multiÃmica para predicciÃn de la agresividad tumoral a partir de biopsia léquida en pacientes de cáncer de prÃstata. |
1R+D |
colombia |
surveprost
Therapeutic area:
Cancer
|
|
ATRYS HEALTH |
análisis de imágenes mádicas |
Diagnostic/Imaging |
Others |
Inteligencia artificial para el análisis de diferentes imágenes mádicas: mamograféas, radiograféas de torax y radiograféas osteo-articulares |
2PreV |
España, Colombia, Peró |
análisis de imágenes mádicas
Therapeutic area:
Others
|
 |
Biocross |
e4Risk Quantitative |
Biomarkers / Diagnostic |
Central Nervous System |
Determination of ApoE4 plasma quantification as a reliable predictor of pathological concentrations of Abeta peptide, Tau and phosphotau in cerebrospinal fluid of patients with clinical suspiction of Alzheimer�s Disease. |
2PreV |
|
e4Risk Quantitative
Therapeutic area:
Central Nervous System
|
|
Biocross |
Degenerative Dementia test |
Biomarkers / Diagnostic |
Central Nervous System |
The Degenerative Dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD.
The DD test is conceived as a �screening� tool for use i |
2PreV |
Europe |
Degenerative Dementia test
Therapeutic area:
Central Nervous System
|
|
Biocross |
e4Risk |
Biomarkers / Diagnostic |
Central Nervous System |
e4Risk is a non-genetic, cost effective, and highly reliable test to evaluate the risk to develop late onset Alzheimer�s Disease. The test detects the presence of the ApoE4 protein in human blood plasma using high-throughput chemical chemistry analyzer. |
5RTM |
Europe |
e4Risk
Therapeutic area:
Central Nervous System
|
|
Biocross |
AD Dementia test |
Biomarkers / Diagnostic |
Central Nervous System |
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patien |
2PreV |
Europe |
AD Dementia test
Therapeutic area:
Central Nervous System
|
 |
BIOHOPE |
Janus kinase (JAK) Inhibitors IMMUNOBIOGRAM |
Biomarkers / Diagnostic |
Autoimmune & Inflammation |
IVD under development with potential application to different immune and inflammatory diseases. It allows to determine the patient's response to Janus kinase (JAK) Inhibitors drugs. |
2PreV |
Spain |
Janus kinase (JAK) Inhibitors IMMUNOBIOGRAM
Therapeutic area:
Autoimmune & Inflammation
|
|
BIOHOPE |
MTX-cell ARTHRITIS |
Biomarkers / Diagnostic |
Autoimmune & Inflammation |
IVD in clinical validation stage that will help to define the best immunosuppressant combination possible for the selection of first line treatment in a certain patient suffering rheumatoid arthritis. |
3CV |
Spain |
MTX-cell ARTHRITIS
Therapeutic area:
Autoimmune & Inflammation
|
|
BIOHOPE |
Transplant IMMUNOBIOGRAM |
Biomarkers / Diagnostic |
Kidney and Genitourinary system
Musculoskeletal Disorders |
CE marked IVD test that allow the doctor to select the most adequate immunosuppressive regimen for each patient. Market launch under a commercial agreement with Palex Medical. |
5RTM |
Spain, Denmark, Germany, Poland, USA |
Transplant IMMUNOBIOGRAM
Therapeutic area:
Kidney and Genitourinary system
Musculoskeletal Disorders
|
 |
BIOLAN HEALTH |
BIOLAN HEALTH COVID-19 Antigen Rapid Test-Self Test |
Diagnostic |
Infections |
The BIOLAN HEALTH COVID-19 Antigen Rapid Test-Self Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleoclapsid antigen of SARS-CoV-2 virus in nasal swab specimens in only 15-20 minutes, for self-diagnosis |
5RTM |
Spain |
BIOLAN HEALTH COVID-19 Antigen Rapid Test-Self Test
Therapeutic area:
Infections
|
|
BIOLAN HEALTH |
BIOLAN HEALTH COVID-19 Antigen Rapid Test |
Diagnostic |
Infections |
The BIOLAN HEALTH COVID-19 Antigen Rapid Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleoclapsid antigen of SARS-CoV-2 virus in nasal swab specimens in only 15-20 minutes, for professional use. |
5RTM |
Spain |
BIOLAN HEALTH COVID-19 Antigen Rapid Test
Therapeutic area:
Infections
|
|
BIOLAN HEALTH |
BIOLAN HEALTH Serological Rapid Test, COVID-19 IgG/IgM |
Diagnostic |
Infections |
Serological Test COVID-19 IgG / IgM Rapid Test Cassette allows to quickly, easily and accurately detect antibodies against SARS-CoV-2 in people who are or have been infected by the virus that causes COVID-19. |
5RTM |
Spain |
BIOLAN HEALTH Serological Rapid Test, COVID-19 IgG/IgM
Therapeutic area:
Infections
|
|
BIOLAN HEALTH |
OSAXYL 7000: for lactose intolerance diagnosis |
Diagnostic |
Digestive System |
The OSAXYL measurement system is a portable tool that allows accurate and reliable diagnosis of hypolactasia (lactose intolerance) by detecting xylose in urine. |
5RTM |
Spain |
OSAXYL 7000: for lactose intolerance diagnosis
Therapeutic area:
Digestive System
|
.png) |
Biotechnology Assets |
CLICK-DIAGNOSTIC |
Diagnostic |
Others |
Splittera technology enhances the sensibility and accuracy of diagnostic systems. Already licensed in non-exclusivity for IVD systems to Biokit |
5RTM |
|
CLICK-DIAGNOSTIC
Therapeutic area:
Others
|
 |
CIBER |
New predictive method for the progression of colorectal cancer |
Biomarkers |
Cancer |
It has been patented a new fetal 'gene signature’ capable to predict the worse evolution of the CRC patients who could suffer a relapse after chemotherapeutic regime or surgery. |
2PreV |
Spain |
New predictive method for the progression of colorectal cancer
Therapeutic area:
Cancer
|
|
CIBER |
Haptens, antibodies and method to detect pseudomonas aeruginosa infections |
Diagnostic |
Infections |
Pseudomonas aeruginosa |
1R+D |
Spain |
Haptens, antibodies and method to detect pseudomonas aeruginosa infections
Therapeutic area:
Infections
|
|
CIBER |
SARS-CoV-2 immunogenic polypeptide, anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
Others |
Infections
Respiratory and Pulmonary system |
SARS-COV-2 |
2PreV |
|
SARS-CoV-2 immunogenic polypeptide, anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
Therapeutic area:
Infections
Respiratory and Pulmonary system
|
|
CIBER |
Biomarkers and method to predict or predict response to treatment with BRAF and MEK inhibitors (BRAFi + MEKi) and for patient follow-up |
Biomarkers / Diagnostic |
Cancer |
Genetic biomarkers, Cancer |
1R+D |
|
Biomarkers and method to predict or predict response to treatment with BRAF and MEK inhibitors (BRAFi + MEKi) and for patient follow-up
Therapeutic area:
Cancer
|
|
CIBER |
PredictivModel to predict the development of type 2 diabetes mellitus using miRNAs |
Biomarkers / Diagnostic |
Metabolic / Endocrinology |
Type 2 diabetes mellitus (T2DM) |
1R+D |
|
PredictivModel to predict the development of type 2 diabetes mellitus using miRNAs
Therapeutic area:
Metabolic / Endocrinology
|
|
CIBER |
INFORMATIVE BIOMARKERS OF PORTAL HYPERTENSION |
Biomarkers / Diagnostic |
Blood and Lymphatic systems |
Non-invasive method to identify patients suffering from portal hypertension based on the detection of two biomarkers. This one, provides robustness and precision for identifying patients suffering from PH and stratifying those that have CSPH. |
1R+D |
Spain |
INFORMATIVE BIOMARKERS OF PORTAL HYPERTENSION
Therapeutic area:
Blood and Lymphatic systems
|
|
CIBER |
USE OF AN MNK kinase inhibitor for the treatment of Triple-negative breast cancer |
Biomarkers / Diagnostic |
Cancer
Women´s health |
breast cancer |
1R+D |
|
USE OF AN MNK kinase inhibitor for the treatment of Triple-negative breast cancer
Therapeutic area:
Cancer
Women´s health
|
|
CIBER |
SALIVA-BASED DIAGNOSTIC TEST FOR EOSINOPHILIC OESOPHAGITIS |
Biomarkers |
Digestive System |
This invention provides a method to analyse the diagnosis and/or prognosis of Eosinophilic Oesophagitis (EoE), using determination and quantification of certain salivary biomarkers. |
1R+D |
Spain |
SALIVA-BASED DIAGNOSTIC TEST FOR EOSINOPHILIC OESOPHAGITIS
Therapeutic area:
Digestive System
|
|
CIBER |
BIOMARKERS AND DIAGNOSTIC METHOD FOR MODY NHF1A |
Biomarkers / Diagnostic |
Metabolic / Endocrinology |
New method for the diagnosis and prognosis of the Maturity Onset Diabetes of the Young carrying deleterious HNF1A alleles (MODY HNF1A) by using biomarkers based on microRNAs(miRNAs) and ultrasensitive C-reactive protein (PCR-hs). |
1R+D |
Spain |
BIOMARKERS AND DIAGNOSTIC METHOD FOR MODY NHF1A
Therapeutic area:
Metabolic / Endocrinology
|
|
CIBER |
ALZHEIMER'S DISEASE DIAGNOSTIC BIOMARKER, A METHOD AND KIT BASED ON THE SAME |
Biomarkers / Diagnostic |
Central Nervous System |
It is an in vitro method for the diagnosis of Alzheimer's disease in which the glycosylation pattern of sAPPα and / or sAPPβ in a biological sample is determined. |
1R+D |
Spain |
ALZHEIMER'S DISEASE DIAGNOSTIC BIOMARKER, A METHOD AND KIT BASED ON THE SAME
Therapeutic area:
Central Nervous System
|
|
CIBER |
Methods for the measurement of protein C and activated protein C |
Biomarkers / Diagnostic |
Autoimmune & Inflammation
Infections |
Sepsis or septic shock |
2PreV |
Spain |
Methods for the measurement of protein C and activated protein C
Therapeutic area:
Autoimmune & Inflammation
Infections
|
|
CIBER |
NON-INVASIVE METHOD FOR COLORECTAL CANCER DETECTION |
Biomarkers |
Cancer |
A new non-invasive method (so called miRFec) with better performance for identifying patients with colorectal cancer (CRC) and advanced adenomas (AA). |
1R+D |
Spain |
NON-INVASIVE METHOD FOR COLORECTAL CANCER DETECTION
Therapeutic area:
Cancer
|
|
CIBER |
Epigenetic biomarkers for the diagnosis and prevention of the evolution of obesity |
Biomarkers / Diagnostic |
Metabolic / Endocrinology |
IBIMA, SAS, University of Málaga and Consorcio Centro de Investigación Biomédica en Red (CIBER) has developed a new methodology useful in the diagnosis and prevention of the evolution of obesity. |
1R+D |
Spain |
Epigenetic biomarkers for the diagnosis and prevention of the evolution of obesity
Therapeutic area:
Metabolic / Endocrinology
|
|
CIBER |
Method for rapid detection of Candida auris and diagnosis of infection caused by this pathogen |
Diagnostic |
Infections |
Candida auris |
2PreV |
Spain |
Method for rapid detection of Candida auris and diagnosis of infection caused by this pathogen
Therapeutic area:
Infections
|
|
CIBER |
ceRNA profile to predict response to immunotherapy in cancer patients |
Diagnostic |
Cancer |
Cancer |
2PreV |
|
ceRNA profile to predict response to immunotherapy in cancer patients
Therapeutic area:
Cancer
|
|
CIBER |
BIOSIGNATURES FOR ULCERATIVE COLITIS |
Biomarkers |
Digestive System |
Biosignature to manage the non-responder corticosteroids patients with personalized approach. |
1R+D |
Spain |
BIOSIGNATURES FOR ULCERATIVE COLITIS
Therapeutic area:
Digestive System
|
|
CIBER |
SEPARATION-OF-FUNCTION I KAPPA B ALPHA MUTANTS |
Biomarkers / Diagnostic |
Cancer |
Cancer |
2PreV |
|
SEPARATION-OF-FUNCTION I KAPPA B ALPHA MUTANTS
Therapeutic area:
Cancer
|
|
CIBER |
METHOD FOR MONITORING OR PREDICTING WHETHER A PATIENT SUFFERING FROM OBESITY IS RESPONDING OR WILL RESPOND TO A VERY-LOW-CALORIE KETOGENIC DIET (VLCKD) |
Biomarkers / Diagnostic |
Metabolic / Endocrinology |
Obesity |
2PreV |
|
METHOD FOR MONITORING OR PREDICTING WHETHER A PATIENT SUFFERING FROM OBESITY IS RESPONDING OR WILL RESPOND TO A VERY-LOW-CALORIE KETOGENIC DIET (VLCKD)
Therapeutic area:
Metabolic / Endocrinology
|
|
CIBER |
BIOMARKERS TO PREDICT LUNG OVERSTRETCHING |
Biomarkers / Diagnostic |
Respiratory and Pulmonary system |
Biomarkers to predict Lung damage |
3CV |
|
BIOMARKERS TO PREDICT LUNG OVERSTRETCHING
Therapeutic area:
Respiratory and Pulmonary system
|
|
CIBER |
IDENTIFICATION OF METABOLOMIC SIGNATURES IN URINE SAMPLES FOR TUBERCULOSIS DIAGNOSIS |
Biomarkers / Diagnostic |
Infections
Others |
diagnosis of tuberculosis |
2PreV |
|
IDENTIFICATION OF METABOLOMIC SIGNATURES IN URINE SAMPLES FOR TUBERCULOSIS DIAGNOSIS
Therapeutic area:
Infections
Others
|
|
CIBER |
PREDICTION OF ACUTE RESPIRATORY DISTRESS IN COVID-19 PATIENTS |
Diagnostic |
Respiratory and Pulmonary system |
SARS-COV-2 |
2PreV |
|
PREDICTION OF ACUTE RESPIRATORY DISTRESS IN COVID-19 PATIENTS
Therapeutic area:
Respiratory and Pulmonary system
|
|
CIBER |
METHOD FOR EARLY TAKO-TSUBO CARDIOMIOPHATY PROGNOSIS IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE |
Diagnostic |
Respiratory and Pulmonary system |
ANEURYSMAL SUBARACHNOID HEMORRHAGE |
2PreV |
|
METHOD FOR EARLY TAKO-TSUBO CARDIOMIOPHATY PROGNOSIS IN PATIENTS WITH ANEURYSMAL SUBARACHNOID HEMORRHAGE
Therapeutic area:
Respiratory and Pulmonary system
|
|
CIBER |
CIRCULATING miRNAS AS BIOMARKERS FOR DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER´S DISEASE |
Biomarkers / Diagnostic |
Central Nervous System |
Our research group is developing a cost-effective molecular kit based on the analysis of a miRNA signature as non-invasive blood-biomarker for early diagnosis of Alzheimer’s disease. |
1R+D |
Spain |
CIRCULATING miRNAS AS BIOMARKERS FOR DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER´S DISEASE
Therapeutic area:
Central Nervous System
|
|
CIBER |
Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques |
Diagnostic |
Central Nervous System |
Alzheimer disease |
2PreV |
Spain |
Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques
Therapeutic area:
Central Nervous System
|
|
CIBER |
Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques |
Biomarkers / Diagnostic |
Central Nervous System |
In vitro method for diagnosis, prognosis and monitoring of Alzheimer's disease using the metabolic profile in serum of an individual. The method includes a NMR acquisition protocol, a mathematical algorithm and a software for data processing. |
1R+D |
Spain |
Method for diagnosis, prognosis and monitoring of Alzheimer disease using metabolomic techniques
Therapeutic area:
Central Nervous System
|
|
CIBER |
METHOD FOR PREDICTING MORTALITY IN COVID-19 PATIENTS |
Diagnostic |
Respiratory and Pulmonary system |
SARS-CoV-2 |
2PreV |
|
METHOD FOR PREDICTING MORTALITY IN COVID-19 PATIENTS
Therapeutic area:
Respiratory and Pulmonary system
|
 |
DIOMUNE SL |
SEPSISpredict |
Biomarkers / Diagnostic |
Cardiovascular and circulatory systems
Infections |
Heart Infarction |
2PreV |
Spain |
SEPSISpredict
Therapeutic area:
Cardiovascular and circulatory systems
Infections
|
 |
FERRER |
EPICUP (FAB-115) |
Diagnostic |
Cancer |
Cancer of Unkown Primary |
5RTM |
Europe |
EPICUP (FAB-115)
Therapeutic area:
Cancer
|
|
FERRER |
EPIBREAST (FAB-118) |
Diagnostic |
Cancer |
Breast Cancer |
1R+D |
Europe |
EPIBREAST (FAB-118)
Therapeutic area:
Cancer
|
 |
FLOMICS BIOTECH |
Flomics liquid biopsy |
Biomarkers / Diagnostic |
Cancer |
Liquid biopsy for the early detection of multiple types of cancer |
2PreV |
Spain |
Flomics liquid biopsy
Therapeutic area:
Cancer
|
|
FLOMICS BIOTECH |
Flomics CA liquid biopsy |
Biomarkers / Diagnostic |
Central Nervous System |
Liquid biopsy for the early detection of Cerebellar Atrophy |
2PreV |
|
Flomics CA liquid biopsy
Therapeutic area:
Central Nervous System
|
 |
FUND. PROGRESO Y SALUD |
FISEVI-19002 MedicalForms: Clinical Information Modeling Tool |
Others |
Others |
Clinical Information Modeling Tool |
1R+D |
|
FISEVI-19002 MedicalForms: Clinical Information Modeling Tool
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
GENYO-19002 METHOD OF OBTAINING USEFUL DATA TO DIAGNOSE HEREDITARY HEMORRHAGIC TELANGIECTASIA |
Diagnostic |
Cardiovascular and circulatory systems |
Method of obtaining useful data to diagnose hereditary hemorrhagic telangiectasia. |
1R+D |
|
GENYO-19002 METHOD OF OBTAINING USEFUL DATA TO DIAGNOSE HEREDITARY HEMORRHAGIC TELANGIECTASIA
Therapeutic area:
Cardiovascular and circulatory systems
|
|
FUND. PROGRESO Y SALUD |
FIBAO-19010, Biomarkers for non-invasive diagnosis of pancreatic ductal adenocarcinoma |
Biomarkers / Diagnostic |
Cancer |
Pancreatic ductal adenocarcinoma |
2PreV |
SPAIN |
FIBAO-19010, Biomarkers for non-invasive diagnosis of pancreatic ductal adenocarcinoma
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FIBAO-19006 y 09 Gene therapy with hokD and ldrB genes for cancer treatment |
Others |
Cancer |
Gene Therapy - Cancer |
2PreV |
SPAIN |
FIBAO-19006 y 09 Gene therapy with hokD and ldrB genes for cancer treatment
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-20015 HemoPer: APP for the management of antithrombotics in perioperative, emergency and COVID19 context |
Others |
Others |
APP for the management of antithrombotics in perioperative, emergency and COVID19 context |
1R+D |
|
FIMABIS-20015 HemoPer: APP for the management of antithrombotics in perioperative, emergency and COVID19 context
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-21005 CUIDAVEN |
Others |
Others |
App for the Care of Venous Devices |
1R+D |
|
FIMABIS-21005 CUIDAVEN
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-20034 Lactoperoxidase as a potential diagnostic method for the presence of Parkinson's disease and response to treatment |
Diagnostic |
Central Nervous System |
Parkinson, Lactoperoxidase as a potential diagnostic method for the presence of Parkinson's disease and response to treatment |
1R+D |
|
FIMABIS-20034 Lactoperoxidase as a potential diagnostic method for the presence of Parkinson's disease and response to treatment
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FISEVI-15004 Portable vest for the application of pulmonary therapy and associated procedure |
Others |
Others |
Portable vest for the application of pulmonary therapy and associated procedure |
1R+D |
|
FISEVI-15004 Portable vest for the application of pulmonary therapy and associated procedure
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
GENYO-20003 SYSTEM FOR THE SIMULTANEOUS DETECTION OF CHROMOSOME ALTERATIONS THROUGH SEQUENCING, CYTOMETRY AND IMAGE. |
Diagnostic |
Others |
SYSTEM FOR THE SIMULTANEOUS DETECTION OF CHROMOSOME ALTERATIONS THROUGH SEQUENCING, CYTOMETRY AND IMAGE. |
1R+D |
|
GENYO-20003 SYSTEM FOR THE SIMULTANEOUS DETECTION OF CHROMOSOME ALTERATIONS THROUGH SEQUENCING, CYTOMETRY AND IMAGE.
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
FISEVI-20011 FEN-COVID-19 |
Diagnostic |
Others |
Covid-19 |
1R+D |
|
FISEVI-20011 FEN-COVID-19
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
GENYO-21001 MyPROSLE: a new system to measure the personalized molecular dysregulated profiles of Systemic Lupus Erythematosus patients |
Diagnostic |
Autoimmune & Inflammation |
MyPROSLE: a new system to measure the personalized molecular dysregulated profiles of Systemic Lupus Erythematosus patients |
1R+D |
|
GENYO-21001 MyPROSLE: a new system to measure the personalized molecular dysregulated profiles of Systemic Lupus Erythematosus patients
Therapeutic area:
Autoimmune & Inflammation
|
|
FUND. PROGRESO Y SALUD |
FIBICO-19012 Use of splicing factors as therapeutic targets in prostate cancer. |
Diagnostic |
Cancer |
Use of splicing factors as therapeutic targets in prostate cancer. |
1R+D |
|
FIBICO-19012 Use of splicing factors as therapeutic targets in prostate cancer.
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-20015 HemoPer: APP for the management of antithrombotics in perioperative, emergency and COVID19 context |
Others |
Others |
Covid-19 |
1R+D |
|
FIMABIS-20015 HemoPer: APP for the management of antithrombotics in perioperative, emergency and COVID19 context
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
FISEVI-18026 CellCount-Master |
Others |
|
SYSTEM AND METHOD OF QUANTIFICATION AND CHARACTERIZATION OF CLUSTERS ASSOCIATED WITH CIRCULATING TUMOR CELLS (CTCs) |
1R+D |
|
FISEVI-18026 CellCount-Master
Therapeutic area:
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-14005 Breast cancer biomarkers |
Biomarkers |
Cancer |
Breast cancer |
2PreV |
|
FIMABIS-14005 Breast cancer biomarkers
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FISEVI-15028 Mobile application for the monitoring and diagnosis of surgical wound infections on an outpatient basis using an image-based telemedicine system (Scarcheck) |
Diagnostic |
|
Mobile application for the monitoring and diagnosis of surgical wound infections on an outpatient basis using an image-based telemedicine system (Scarcheck) |
1R+D |
|
FISEVI-15028 Mobile application for the monitoring and diagnosis of surgical wound infections on an outpatient basis using an image-based telemedicine system (Scarcheck)
Therapeutic area:
|
|
FUND. PROGRESO Y SALUD |
FISEVI-20005 Equivalent dose converter between different drugs |
Others |
Others |
Equivalent dose converter between different drugs |
1R+D |
|
FISEVI-20005 Equivalent dose converter between different drugs
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-21007 Predict plus Prevent |
Others |
Substance Abuse |
Mental Health, Predict plus Prevent is a set of calculators to predict the appearance of future episodes of depression, anxiety and / or problems with alcohol |
1R+D |
|
FIMABIS-21007 Predict plus Prevent
Therapeutic area:
Substance Abuse
|
|
FUND. PROGRESO Y SALUD |
GENYO-13001 / FIMABIS-13009 |
Biomarkers |
Autoimmune & Inflammation |
Lupus erythematosus / Allergy |
2PreV |
Europe |
GENYO-13001 / FIMABIS-13009
Therapeutic area:
Autoimmune & Inflammation
|
 |
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
Biomarkers for detecting renal disease |
Biomarkers / Diagnostic |
Kidney and Genitourinary system |
Biomarker for predicting the response of patients suffering from renal disease |
1R+D |
Spain |
Biomarkers for detecting renal disease
Therapeutic area:
Kidney and Genitourinary system
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
GPCRA RECEPTOR AGONIST APTAMERS |
Diagnostic |
Others |
Diagnostic and therapeutic value |
1R+D |
Spain |
GPCRA RECEPTOR AGONIST APTAMERS
Therapeutic area:
Others
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
COMPOUNDS FOR USE IN THE TREATMENT AND/OR SEPTICEMIA PREVENTION |
Diagnostic |
Infections
Others |
The present invention relates to proteins comprising the catalytic domain of a cytotoxic necrotic factor from Yersinia pseudotuberculosis
(CNFY), for use in the treatment and/or prevention of septicemia and/or edema associated with sepsis in one subject. |
1R+D |
Spain |
COMPOUNDS FOR USE IN THE TREATMENT AND/OR SEPTICEMIA PREVENTION
Therapeutic area:
Infections
Others
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
NEW METHOD FOR IDENTIFYING RISK FACTORS ASSOCIATED TO HYPERTENSION |
Diagnostic |
Cardiovascular and circulatory systems
Kidney and Genitourinary system |
Method and kit for identifying albuminuria development risk,renal injury risk and cardiovascular risk in a hypertensive human subject |
1R+D |
Spain |
NEW METHOD FOR IDENTIFYING RISK FACTORS ASSOCIATED TO HYPERTENSION
Therapeutic area:
Cardiovascular and circulatory systems
Kidney and Genitourinary system
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
SEPT6-ABL2 FUSION FOR USE IN THE DIAGNOSIS AND/OR TREATMENT OF CANCER |
Diagnostic |
Others |
The invention refers to the medical field. Particularly, the present invention refers to a cell linecharacterized by comprising the fusion gene [SEPT6-ABL2] within its genetic material, or the fusion transcript [SEPT6-ABL2]. |
1R+D |
Spain |
SEPT6-ABL2 FUSION FOR USE IN THE DIAGNOSIS AND/OR TREATMENT OF CANCER
Therapeutic area:
Others
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
Differential biomarkers of severity in asthma |
Biomarkers |
Respiratory and Pulmonary system |
Biomarkers of several clinical phenotypes of asthma |
1R+D |
Spain |
Differential biomarkers of severity in asthma
Therapeutic area:
Respiratory and Pulmonary system
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
IN VIVO LENTIVIRAL GENE THERAPY FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 |
Others |
Others |
Researchers propose the use of LV based on the vector used for the treatment of Haemophilia B for the treatment of primary hyperoxaluria type 1 |
1R+D |
Spain |
IN VIVO LENTIVIRAL GENE THERAPY FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1
Therapeutic area:
Others
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
MESENCHYMAL CELLS FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION |
Others |
Ophthalmology and optometry |
The invention relates to a substantially pure population of mesenchymal stem cells for use in the prophylactic and/or therapeutic treatment of Meibomian Gland Dysfunction. |
1R+D |
Spain |
MESENCHYMAL CELLS FOR USE IN THE PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION
Therapeutic area:
Ophthalmology and optometry
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
"BACTERIOPHAGE SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA (1 fago)" |
Others |
Others |
The present invention refers to the medial field. Particularly, the present invention refers to a bacteriophage deposited at the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ) with deposit number DSM34223on 17th of March 2022. In a pref |
1R+D |
Spain |
"BACTERIOPHAGE SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY PSEUDOMONAS AERUGINOSA (1 fago)"
Therapeutic area:
Others
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
"BACTERIOPHAGES SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY KLEBSIELLA PNEUMONIAE (6 fagos)" |
Others |
Others |
The present invention refers to a bacteriophage deposited at the German Collection of Microorganisms and Cell Cultures GmbH (Leibniz Institute) (DSMZ)with deposit number DSM34222, and to a bacteriophage characterized by comprising a nucleic acid consist |
1R+D |
Spain |
"BACTERIOPHAGES SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY KLEBSIELLA PNEUMONIAE (6 fagos)"
Therapeutic area:
Others
|
|
FUNDACIÓN JIMÉNEZ DÃAZ (Instituto de Investigación Sanitaria) |
"BACTERIOPHAGE SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY MYCOBACTERIUM ABSCESSUS (3 fagos)" |
Others |
Others |
The present invention refers to a bacteriophage deposited at the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ) with deposit number DSM 34221, or a bacteriophage comprising a nucleic acid having at least 95% of identity with the nucleic |
1R+D |
|
"BACTERIOPHAGE SUITABLE FOR TREATING A BACTERIAL INFECTION CAUSED BY MYCOBACTERIUM ABSCESSUS (3 fagos)"
Therapeutic area:
Others
|
 |
Fundacion MEDINA |
In vitro tests for toxicity, safety, ADME and plasma efficacy |
Diagnostic/Imaging |
Others |
Cytotoxicity, Neurotoxicity, Mitochondrial Toxicity, Cardiotoxicity, ADME tox |
5RTM |
Spain |
In vitro tests for toxicity, safety, ADME and plasma efficacy
Therapeutic area:
Others
|
|
Fundacion MEDINA |
Biomarkers Platform |
Biomarkers / Diagnostic |
Cancer |
Lung Colon Breast Pancreas |
3CV |
Spain |
Biomarkers Platform
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
Metabolomics Biomarkers Identification Platform |
Biomarkers / Diagnostic |
Cancer
Infections
Metabolic / Endocrinology |
Cancer Infectious Metabolism and Infectious Biomarkers |
3CV |
Spain |
Metabolomics Biomarkers Identification Platform
Therapeutic area:
Cancer
Infections
Metabolic / Endocrinology
|
 |
IIS La Fe |
Biomarkers predictive of cardiac ischemia risk |
Biomarkers / Diagnostic |
Cardiovascular and circulatory systems |
Circulating miRNAs whose altered levels in serum/plasma of patients may be related to the risk of suffering anischaemic event. |
2PreV |
Spain |
Biomarkers predictive of cardiac ischemia risk
Therapeutic area:
Cardiovascular and circulatory systems
|
|
IIS La Fe |
miRNA based Diagnostic method for bladder cancer |
Biomarkers / Diagnostic |
Cancer |
miRNA profiling basen in cuantification of 7 miRNAs for the detection and stratification of patients suffering from bladder cancer |
2PreV |
Spain |
miRNA based Diagnostic method for bladder cancer
Therapeutic area:
Cancer
|
|
IIS La Fe |
Method for predicting response to continuous positive air pressure treatment |
Diagnostic |
Respiratory and Pulmonary system |
Predictive method of response to treatment with continuous positive air pressure (CPAP) in patients with sleep apnea and resistant hypertension. |
1R+D |
Spain |
Method for predicting response to continuous positive air pressure treatment
Therapeutic area:
Respiratory and Pulmonary system
|
|
IIS La Fe |
Composition comprising oxylipins present in human milk derived small extracellular vesicles and its use in the prevention and treatment of intestinal diseases |
Biomarkers / Diagnostic |
Digestive System |
Breast milk derived Evs as a combination of pro-resolutive oxilipines (14-HDHA, 17-HDHA, 19,20-DiHDPA). Potential beneficial effects for prevent intestinal disfunction and achieving digestive system maturity. |
1R+D |
Spain |
Composition comprising oxylipins present in human milk derived small extracellular vesicles and its use in the prevention and treatment of intestinal diseases
Therapeutic area:
Digestive System
|
|
IIS La Fe |
Determination of autoantibodies in autoimmune patients Ro/SSA+ |
Biomarkers / Diagnostic |
Autoimmune & Inflammation |
Measurement in a piezoelectric resonator of the relationship between different variables of an interfacial process of molecular recognition antigen-antibody for the screening of samples of autoimmune patients. |
1R+D |
Spain |
Determination of autoantibodies in autoimmune patients Ro/SSA+
Therapeutic area:
Autoimmune & Inflammation
|
|
IIS La Fe |
Method for predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy |
Biomarkers / Diagnostic |
Cancer
Cardiovascular and circulatory systems |
In vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy 5 based on the determination of the expression levels of a combination of 10 circulating miRNAs |
2PreV |
|
Method for predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy
Therapeutic area:
Cancer
Cardiovascular and circulatory systems
|
 |
IMMUNOSTEP |
Disposable device for leukocyte separation |
Diagnostic |
Autoimmune & Inflammation
Blood and Lymphatic systems |
Hematological malignancies |
2PreV |
Spain |
Disposable device for leukocyte separation
Therapeutic area:
Autoimmune & Inflammation
Blood and Lymphatic systems
|
|
IMMUNOSTEP |
Infiltration in CNS |
Diagnostic |
Cancer |
Detection of Leptomeningeal disease |
4Reg. |
Worldwide |
Infiltration in CNS
Therapeutic area:
Cancer
|
|
IMMUNOSTEP |
Anti-SARS-CoV-2 Test Multiantégeno para IgG+IgA+IgM |
Diagnostic/Imaging |
Infections |
Multiantigen IgG+IgA+IgM Assay is a multiplex, microsphere-based, highly sensitive and specific assay that measure the presence or absence of antibodies against four different SARS-CoV-2 antigens simultaneously. |
4Reg. |
EUROPA |
Anti-SARS-CoV-2 Test Multiantégeno para IgG+IgA+IgM
Therapeutic area:
Infections
|
|
IMMUNOSTEP |
HemodiluciÃn (Bmplex) |
Diagnostic |
Blood and Lymphatic systems |
Detection of hemodilution in bone marrow samples |
3CV |
Worldwide |
HemodiluciÃn (Bmplex)
Therapeutic area:
Blood and Lymphatic systems
|
|
IMMUNOSTEP |
ThromboStep |
Diagnostic |
Cardiovascular and circulatory systems |
Autoimmune Thrombocytopenia Diagnosis by flow cytometry |
5RTM |
Europe |
ThromboStep
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Ingenasa / Gold Standard Diagnostics Madrid |
INgezim® COVID RBD-DR |
Diagnostic |
Infections |
ELISA for Antibody detection of COVID 19 at Human and animals. |
3CV |
|
INgezim® COVID RBD-DR
Therapeutic area:
Infections
|
 |
IRYCIS |
New aptamers for diagnosis of COVID19 |
Biomarkers / Diagnostic |
Autoimmune & Inflammation
Others |
Development of therapeutic aptamers against the SARS-Cov2 spike protein and different highly conserved viral peptides in regions involved in the entry of the virus |
1R+D |
|
New aptamers for diagnosis of COVID19
Therapeutic area:
Autoimmune & Inflammation
Others
|
|
IRYCIS |
New aptamers against HCV |
Biomarkers / Diagnostic |
Infections |
C hepatitis |
2PreV |
|
New aptamers against HCV
Therapeutic area:
Infections
|
|
IRYCIS |
New biomarkers to identify good responders to cis-platinum in lug cancer |
Biomarkers / Diagnostic |
Cancer |
New biomarkers based on aptamers technology (target MAFG) to identify good responders to cis-platinum in lug cancer |
2PreV |
|
New biomarkers to identify good responders to cis-platinum in lug cancer
Therapeutic area:
Cancer
|
|
IRYCIS |
Aptamers against MNK1 for the treatment of breast cancer |
Others |
Cancer |
Aptamers against MNK1 for the treatment of breast cancer |
2PreV |
|
Aptamers against MNK1 for the treatment of breast cancer
Therapeutic area:
Cancer
|
|
IRYCIS |
Diagnosis of melanoma with support of AI |
Diagnostic |
Dermatology |
Artificial intelligence in dermatology |
5RTM |
|
Diagnosis of melanoma with support of AI
Therapeutic area:
Dermatology
|
|
IRYCIS |
Diagnosis of osteoporosis with support of AI |
Diagnostic |
Musculoskeletal Disorders
Others |
Osteoporosis |
1R+D |
|
Diagnosis of osteoporosis with support of AI
Therapeutic area:
Musculoskeletal Disorders
Others
|
|
IRYCIS |
Predictive biomarkers of response after neoadjuvant therapy in locally advanced rectal adenocarcinoma |
Biomarkers |
Cancer |
rectal adenocarcinoma |
1R+D |
|
Predictive biomarkers of response after neoadjuvant therapy in locally advanced rectal adenocarcinoma
Therapeutic area:
Cancer
|
|
IRYCIS |
New biomarkers to predict secundary autoimmunity before the treatment with alemtuzumab in MS |
Biomarkers |
Autoimmune & Inflammation
Central Nervous System |
New method to determine the probability to develop a secondary autoimmune disease before the treatment with alemtuzumab in patients with Multiple Sclerosis |
5RTM |
Spain |
New biomarkers to predict secundary autoimmunity before the treatment with alemtuzumab in MS
Therapeutic area:
Autoimmune & Inflammation
Central Nervous System
|
|
IRYCIS |
miRNA 127 agents for use in the treatment of renal fibrosis |
Biomarkers / Diagnostic |
Kidney and Genitourinary system |
A method of prophylactically or therapeutically treating Chronic kidney disease (CKD) or of reducing the risk of CKD disease progression in a patient comprising expressing miR-127 in the renal cells |
3CV |
Spain |
miRNA 127 agents for use in the treatment of renal fibrosis
Therapeutic area:
Kidney and Genitourinary system
|
|
IRYCIS |
Biomarkers to identify the response to OIT of children allergics to caw milk proteins |
Biomarkers / Diagnostic |
Autoimmune & Inflammation
Others |
Biomarkers based on IgE profile for determining oral immunotherapy treatment response in children with cow’s milk protein allergy (with F. Hospital CI) |
3CV |
Spain |
Biomarkers to identify the response to OIT of children allergics to caw milk proteins
Therapeutic area:
Autoimmune & Inflammation
Others
|
|
IRYCIS |
Noverl biomarkers of acute kidney injury based on miRNAs |
Biomarkers / Diagnostic |
Kidney and Genitourinary system |
The identified panel of miRNAs can detect acute kidney injury (AKI) development before serum creatinine increases |
3CV |
Spain |
Noverl biomarkers of acute kidney injury based on miRNAs
Therapeutic area:
Kidney and Genitourinary system
|
|
IRYCIS |
Biomarkers to identify IFN-BETA drug responders in patients with multiple sclerosis |
Biomarkers / Diagnostic |
Autoimmune & Inflammation
Central Nervous System |
New patented method to identify good responders to Interferon beta (INF-beta) therapy in multiple sclerosis before treatment initiation |
5RTM |
Spain |
Biomarkers to identify IFN-BETA drug responders in patients with multiple sclerosis
Therapeutic area:
Autoimmune & Inflammation
Central Nervous System
|
|
IRYCIS |
Biomarkers to identify ocrelizumab good drug responders in patients with PP multiple sclerosis |
Biomarkers |
Autoimmune & Inflammation
Central Nervous System |
Primary progressive multiple sclerosis |
3CV |
|
Biomarkers to identify ocrelizumab good drug responders in patients with PP multiple sclerosis
Therapeutic area:
Autoimmune & Inflammation
Central Nervous System
|
 |
Leitat |
ELISA kit to detect biomarker levels (S100A7) |
Biomarkers / Diagnostic |
Autoimmune & Inflammation
Cancer |
Diagnosis and prognosis of several cancers |
2PreV |
Spain |
ELISA kit to detect biomarker levels (S100A7)
Therapeutic area:
Autoimmune & Inflammation
Cancer
|
|
Leitat |
COVID |
Diagnostic |
Infections |
Antibodies with several tags and different formats for diagnostic use in COVID |
2PreV |
|
COVID
Therapeutic area:
Infections
|
|
Leitat |
ELISA kit to detect biomarker levels (S100P) |
Biomarkers / Diagnostic |
Autoimmune & Inflammation
Cancer |
Diagnosis and prognosis of Pancreatic cancer, colon cancer, others |
2PreV |
Spain |
ELISA kit to detect biomarker levels (S100P)
Therapeutic area:
Autoimmune & Inflammation
Cancer
|
|
Leitat |
ELISA kit to detect biomarker levels (S100A4) |
Biomarkers / Diagnostic |
Autoimmune & Inflammation
Cancer |
Diagnosis and prognosis of Pancreatic cancer, colon cancer, others |
2PreV |
Spain |
ELISA kit to detect biomarker levels (S100A4)
Therapeutic area:
Autoimmune & Inflammation
Cancer
|
|
Leitat |
Tailored-made formulations with nanoencapsulated active compounds |
Others |
Autoimmune & Inflammation
Dermatology |
Atopic dermatitis, psoriasis |
1R+D |
Spain |
Tailored-made formulations with nanoencapsulated active compounds
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Leitat |
Microbiome profile |
Biomarkers |
Cancer
Dental
Dermatology
Digestive System
Metabolic / Endocrinology |
microbiome characterization (including 3 biomes: bacteria, fungi and viruses) and its relantionship with health&disease, response to treatments |
2PreV |
|
Microbiome profile
Therapeutic area:
Cancer
Dental
Dermatology
Digestive System
Metabolic / Endocrinology
|
|
Leitat |
Metabolic profile |
Biomarkers |
Infections |
Helicobacter pylori infection, oxidative stress |
1R+D |
Spain |
Metabolic profile
Therapeutic area:
Infections
|
|
Leitat |
In vitro cellular model for diagnosis |
Biomarkers |
Infections |
Helicobacter pylori virulence |
1R+D |
Spain |
In vitro cellular model for diagnosis
Therapeutic area:
Infections
|
|
Leitat |
Ready-to-use transport kits for xenobiotic interaction studies |
Others |
Others |
To identify xenobiotic interactions for regulatory purposes |
5RTM |
Europe |
Ready-to-use transport kits for xenobiotic interaction studies
Therapeutic area:
Others
|
 |
Life Length |
Telomere Analysis Technology (TAT Test) |
Biomarkers |
Cancer
Cardiovascular and circulatory systems
Others |
Age related diseases, Cancer, Cardiovascular, Degenerative diseases |
5RTM |
Europe, US |
Telomere Analysis Technology (TAT Test)
Therapeutic area:
Cancer
Cardiovascular and circulatory systems
Others
|
 |
Merck / Sysmex Inostics |
Liquid Biopsy RAS Biomarker Testing |
Biomarkers / Diagnostic |
Cancer
Digestive System |
Metastatic colorectal cancer |
1R+D |
Spain |
Liquid Biopsy RAS Biomarker Testing
Therapeutic area:
Cancer
Digestive System
|
 |
NIMGENETICS |
TromboNIM |
Diagnostic |
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes |
Estudio genático de la trombofilia hereditaria dirigido a la identificaciÃn de pacientes con un riesgo incrementado de desarrollar enfermedad tromboembÃlica. Analiza 24 variantes en 18 Genes asociadas a un incremento en el riesgo trombÃtico. Incluye g |
5RTM |
Spain |
TromboNIM
Therapeutic area:
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
|
|
NIMGENETICS |
ExoNIM Personalizado |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
AproximaciÃn de ExoNIM® que permite el diseño de un panel de genes adaptados a las necesidades del especialista.
Las principales ventajas de esta aproximaciÃn son:
1. Posibilidad de ampliaciÃn del análisis por apariciÃn de nuevos séntomas, redefi |
5RTM |
Spain |
ExoNIM Personalizado
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
NIMGENETICS |
KaryoNIM Leukemia |
Diagnostic |
Cancer |
Plataforma genÃmica diseñada por NIMGenetics para la identificaciÃn de biomarcadores en la leucemia linfática crÃnica (LLC), que combina la tecnologéa de array CGH y de SNParray.
1. El array CGH ha demostrado ser la tecnologéa más eficaz en este |
5RTM |
Spain |
KaryoNIM Leukemia
Therapeutic area:
Cancer
|
|
NIMGENETICS |
ExoNIM Plus Epilepsia |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
Abordaje global para el estudio de las distintas formas clénicas de la epilepsia que analiza 223 genes con relevancia clénica a partir de la secuenciaciÃn del exoma completo (ExoNIM®).
La secuencia obtenida queda almacenada, lo que permite la aplicaci |
5RTM |
Spain |
ExoNIM Plus Epilepsia
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
NIMGENETICS |
ExoNIM Dirigido |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
AproximaciÃn al análisis del exoma basada en la selecciÃn de genes asociados al fenotipo del paciente. Tras la secuenciaciÃn de los 19.000 genes del paciente, se analizan aquellos asociados al cuadro clénico. La secuencia completa queda almacenada, l |
5RTM |
Spain |
ExoNIM Dirigido
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
NIMGENETICS |
ExoNIM Trio |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
AproximaciÃn de ExoNIM® basada en la secuenciaciÃn de los 19.000 genes del paciente y, sus progenitories. La informaciÃn genática de los progenitores, permite determinar en las variantes identificadas el patrÃn de herencia. Esta aproximaciÃn facilit |
5RTM |
Spain |
ExoNIM Trio
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
NIMGENETICS |
ExoNIM Clénico |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
AproximaciÃn de ExoNIM® que se focaliza en el análisis de genes con fenotipo OMIM (Online Mendelian Inheritance in Man (OMIM). La secuencia completa queda almacenada, lo que permite la realizaciÃn de diferentes análisis de forma secuencial.
ExoNIM® C |
5RTM |
Spain |
ExoNIM Clénico
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
NIMGENETICS |
TrisoNIM Excellence |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
Test de ADN fetal en sangre materna, mediante secuenciaciÃn masiva de óltima generaciÃn (NGS, Next Generation Sequencing) y la aplicaciÃn del algoritmo NIFTY®. TrisoNIM® es el primer test de ADN fetal realizado éntegramente en España.
TrisoNIM® Exc |
5RTM |
Spain |
TrisoNIM Excellence
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
 |
Oniria Therapeutics |
EpiGold-G |
Biomarkers / Diagnostic |
Cancer |
Detection of epigenetic modifications in liquid biopsies |
1R+D |
|
EpiGold-G
Therapeutic area:
Cancer
|
 |
OPERON |
CT Oligogen |
Biomarkers / Diagnostic |
Infections |
Molecular test for the detection of Chlamydia trachomatis |
5RTM |
Spain |
CT Oligogen
Therapeutic area:
Infections
|
|
OPERON |
CT/NG/MG Oligogen |
Diagnostic |
Infections |
Molecular test for the simultaneous detection of Chlamydia trachomatis, Nisseria gonorrhoeae, and Mycobacterium genitalis. |
5RTM |
Spain |
CT/NG/MG Oligogen
Therapeutic area:
Infections
|
|
OPERON |
MG Oligogen |
Biomarkers / Diagnostic |
Infections |
Test designed for the detection of�Mycoplasma genitalium |
5RTM |
Spain |
MG Oligogen
Therapeutic area:
Infections
|
|
OPERON |
S. PneumoStrip |
Diagnostic |
Respiratory and Pulmonary system |
Molecular test for the serotyping of Streptococcus pneumoniae |
4Reg. |
Spain |
S. PneumoStrip
Therapeutic area:
Respiratory and Pulmonary system
|
|
OPERON |
NG Oligogen |
Biomarkers / Diagnostic |
Infections |
Molecular Test for the detection of�Neisseria goorrhoeae |
5RTM |
Spain |
NG Oligogen
Therapeutic area:
Infections
|
 |
Progenika Biopharma |
Promonitor QUICK - PoC |
Others |
Autoimmune & Inflammation |
Point of Care Therapeutic drug monitoring |
4Reg. |
Spain |
Promonitor QUICK - PoC
Therapeutic area:
Autoimmune & Inflammation
|
|
Progenika Biopharma |
Promonitor - ELISA |
Others |
Autoimmune & Inflammation |
Therapeutic drug monitoring |
5RTM |
Spain |
Promonitor - ELISA
Therapeutic area:
Autoimmune & Inflammation
|
 |
PROMEGA BIOTECH IBÉRICA |
Spectrum Compact CE System |
Diagnostic |
Cancer |
4-capillary instrument labelled as CE to run MSI fragment analysis for cancer diagnosis |
4Reg. |
|
Spectrum Compact CE System
Therapeutic area:
Cancer
|
|
PROMEGA BIOTECH IBÉRICA |
Lumit SARS-CoV 2 |
Diagnostic |
Infections |
Immunoassay kit to detect SARS-CoV 2 |
4Reg. |
|
Lumit SARS-CoV 2
Therapeutic area:
Infections
|
|
PROMEGA BIOTECH IBÉRICA |
Microsatellite Instability Analysis CE-IVD |
Biomarkers / Diagnostic |
Cancer |
Characterize MSI Status by a Fluorescent Multiplex PCR-based method with CE/IVD label |
5RTM |
Global |
Microsatellite Instability Analysis CE-IVD
Therapeutic area:
Cancer
|
 |
QGENOMICS Quantitative Genomic Medicine Laboratories |
qGen clinical exome, qGen Trio, qGen Custom 5-10-50-250-500-1000, qGen pathologies |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
Clinical exome of >6.000 genes.
Trio (adding progenitors), Custom (customized panels), Pathology panels |
5RTM |
Spain |
qGen clinical exome, qGen Trio, qGen Custom 5-10-50-250-500-1000, qGen pathologies
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
Arrays service: qChip Pre, qChip Post , qChip PdC (60-180-400k-1M) |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
Microarrays (60k ISO 15189 certified) |
5RTM |
Spain |
Arrays service: qChip Pre, qChip Post , qChip PdC (60-180-400k-1M)
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
Custom gene expression Microarray |
Biomarkers / Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
Customized gene expression microarray study |
5RTM |
Spain |
Custom gene expression Microarray
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
qCancer: BRCA1/2, Mama, Gine, Colorrectal, Risk, Risk Expanded |
Biomarkers / Diagnostic |
Cancer |
NGS panels to detect the level of hereditary Cancer risk |
5RTM |
Spain |
qCancer: BRCA1/2, Mama, Gine, Colorrectal, Risk, Risk Expanded
Therapeutic area:
Cancer
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
Arrays kits (60-180k, with SNP) |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
Arrays kits to integrate the process in the center |
5RTM |
Spain |
Arrays kits (60-180k, with SNP)
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
qTranscriptome |
Others |
Genetic Diseases and Dysmorphic syndromes |
mRNA analysis through RNA-Seq (30MR 2x150bp) |
5RTM |
Spain |
qTranscriptome
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
qGenEx: Research, Trio, Custom, Pathologies |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
Whole exome of >20.000 genes.
Trio (adding progenitors), Custom (customized panels), Pathology panels. |
5RTM |
Spain |
qGenEx: Research, Trio, Custom, Pathologies
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
qMicrobiome: endometrial and vaginal |
Diagnostic |
Infections
Women´s health |
NGS test (V4 and V5 from rRNA 16S) to detect the endometrial and vaginal bacteria, Candida and HPV. |
5RTM |
Spain |
qMicrobiome: endometrial and vaginal
Therapeutic area:
Infections
Women´s health
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
qCarrier: Plus, Plus Extended Compatibility, Plus Pareja, Auto, Auto Extended Compatibility, qExpect |
Others |
Genetic Diseases and Dysmorphic syndromes |
NGS Carrier Test for Recessive Diseases |
5RTM |
Spain |
qCarrier: Plus, Plus Extended Compatibility, Plus Pareja, Auto, Auto Extended Compatibility, qExpect
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
Custom qPCR |
Others |
Genetic Diseases and Dysmorphic syndromes |
Customized quantitative PCR |
5RTM |
Spain |
Custom qPCR
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
Other molecular tests: MLPA, Sanger, FISH, microsatelites, qCell Identity |
Diagnostic |
Genetic Diseases and Dysmorphic syndromes |
Other molecular tests for validation or specific clinical suspicions |
5RTM |
Spain |
Other molecular tests: MLPA, Sanger, FISH, microsatelites, qCell Identity
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
CGH arrays ad-hoc |
Others |
Genetic Diseases and Dysmorphic syndromes |
Copy Number determination in specific regions |
5RTM |
Spain |
CGH arrays ad-hoc
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
QGENOMICS Quantitative Genomic Medicine Laboratories |
qGenome |
Others |
Genetic Diseases and Dysmorphic syndromes |
Whole genome sequencing (30x coverage), bioinformatic analysis and expert interpretation |
5RTM |
|
qGenome
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
 |
SECUGEN |
Service for the detection and quantification of autoantibodies against CFH and CFI |
Biomarkers |
Autoimmune & Inflammation
Genetic Diseases and Dysmorphic syndromes |
Complement system related disorders |
5RTM |
Spain |
Service for the detection and quantification of autoantibodies against CFH and CFI
Therapeutic area:
Autoimmune & Inflammation
Genetic Diseases and Dysmorphic syndromes
|
|
SECUGEN |
GENOTYPING |
Diagnostic/Imaging |
Ophthalmology and optometry |
Genetic risk for Age related Macular Degeneration |
5RTM |
Worldwide |
GENOTYPING
Therapeutic area:
Ophthalmology and optometry
|
|
SECUGEN |
NEXT GEN SEQUENCING |
Diagnostic/Imaging |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Kidney and Genitourinary system |
Genetic Diagnosis |
5RTM |
Worldwide |
NEXT GEN SEQUENCING
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Kidney and Genitourinary system
|
|
SECUGEN |
DNA SEQUENCING |
Diagnostic/Imaging |
Genetic Diseases and Dysmorphic syndromes |
Genetic Diagnosis |
5RTM |
Worldwide |
DNA SEQUENCING
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
 |
Vicomtech |
HFpred - Predictive model for early detection of decompensation due to heart failure |
Others |
Cardiovascular and circulatory systems |
Predictive model for early detection of decompensation due to heart failure |
2PreV |
España |
HFpred - Predictive model for early detection of decompensation due to heart failure
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Vivia Biotech |
Personalized Medicine Test in Haematological Malignancies |
Diagnostic |
Blood and Lymphatic systems
Cancer |
Acute Myeloid Leukaemia |
5RTM |
Europe |
Personalized Medicine Test in Haematological Malignancies
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
Vivia Biotech |
Personalized Medicine Test in Haematological Malignancies |
Biomarkers / Diagnostic |
Cancer |
Multiple Myeloma |
3CV |
Europe |
Personalized Medicine Test in Haematological Malignancies
Therapeutic area:
Cancer
|
|
Vivia Biotech |
Personalized Medicine Test in Haematological Malignancies |
Biomarkers / Diagnostic |
Blood and Lymphatic systems
Cancer |
Acute Lymphocytic Leukaemia |
3CV |
Europe |
Personalized Medicine Test in Haematological Malignancies
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
Vivia Biotech |
Personalized Medicine Test in Haematological Malignancies |
Biomarkers / Diagnostic |
Blood and Lymphatic systems
Cancer |
Chronic Lymphocytic Leukaemia |
3CV |
Europe |
Personalized Medicine Test in Haematological Malignancies
Therapeutic area:
Blood and Lymphatic systems
Cancer
|